Companion Diagnostics Market

Companion Diagnostics Market - Size,
Share, Outlook, and Opportunity
Analysis, 2018 - 2026
Global Companion Diagnostics Market, By Application(Breast Cancer, Lung
Cancer, Colorectal Cancer, Gastric Cancer, Melanoma),
Technology(Immunohistochemistry, Real-time PCR, Gene Sequencing, FISH),
and Geography - Trends, Analysis and Forecast till 2026
Personalized medicine is the new segment in discussion among healthcare experts around the
globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of
providing a defined structure for companion diagnostic development is driving research activities
in personalized medicine. Diagnosis at molecular level for each individual is of prime importance
to identify the target biomarker before deciding the therapy. Companion diagnostic is one such
emerging field for target biomarker identification reducing clinical trial cost and time to market
the product.
Pharmaceutical companies need to constantly innovate and integrate latest technological
breakthroughs in order to sustain in the companion diagnostics market, given the looming threat
of new technologies posing threat to existing product portfolio and research pipeline. Novartis AG
focuses on R&D for biomarkers with the help of its partner SomaLogic, Inc., once they begin the
process of finalizing the drug candidate. Such pre-work is now part of the routine of drug
development, something that was an alien practice till around a decade ago. The U.S. FDA
released a draft guideline for companion diagnostics in July 2016, providing a structure for the
pharmaceutical companies to co-develop CDx test along with the drug therapies.
Request Sample Copy of this Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/109
Low cost and clinical benefits of companion diagnostics is expected to drive growth of
the market
The ecosystem of pharmaceuticals industry is one of the major factors driving growth of the
companion diagnostics market. The providers of healthcare products and services, and patients
who utilize these products and services is expected to be benefitted by a collaborative approach.
The innovation of CDx helped drug developers in reducing the development costs, developing
highly effective therapeutic products, and improving the time to market by identifying the

effectiveness of a drug against particular biomarkers. Moreover, better treatment outcomes and
lower morbidity risk are benefits offered to the patients. Also, accurate diagnosis and
determination of targeted cancer therapy has become much easier due to advanced
technologies such as PCR, immunohistochemistry, and gene sequencing.
Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug
therapy to the patient. It has become a critical part of targeted cancer therapy that allows for
development of personalized therapy can be developed and administered to the patient. Whole
blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and
identification of targeted disease biomarker. CDx is usually utilized in identifying genetic
mutations and the health and treatment approach implications. In July 2016, the U.S. FDA
released a draft guideline for development of a therapeutic product accompanying an IVD
companion diagnostic. Companion diagnostics include Gleevec (imatinib mesylate) and BCR-ABL
LDT and DAKO C-KIT PharmDx, Herceptin (trastuzumab) and DAKO Herceptest; and Nolvaldex
(tamoxifen) and laboratory-developed estrogen receptor positive test.
Companion diagnostics are beneficial for pharmaceutical companies who face challenges with
respect to high drug development cost, safety and outcome of clinical trials, and long product
approval time. Companion diagnostics lowers development costs, improves time to market and
enhances drug safety by enabling rapid identification of target biomarker and the most effective
drug therapy. For patients, the technology provides better treatment outcomes and lower
morbidity risk. Use of technologies such as PCR, immunohistochemistry, and gene sequencing
has enabled accurate diagnosis and determination of targeted cancer therapy. As the CDx tests
also aid in revealing the off-target effects of a drug along with identification of a molecular
target, CDx have become and indispensable tool for oncologists.
Browse More About the Keyword Market Study @
https://www.coherentmarketinsights.com/market-insight/companion-diagnostics-market-109
Report includes chapters which deeply display the following deliverable about industry:
• Global Companion Diagnostics Market Research Objective and Assumption
• Global Companion Diagnostics Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Global Companion Diagnostics Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Global Companion Diagnostics Market, By Regions
• Global Companion Diagnostics Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Global Companion Diagnostics Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Global Companion Diagnostics Market Manufacturing Cost Analysis including Key Raw Materials
and Key Suppliers of Raw Materials.

• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Global Companion Diagnostics Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Table of Contents of Keyword Market Report:
1. Research Objective and assumption
2. Market Purview
3. Market Dynamics, Regulations, and Trends Analysis
4. Keyword Market, By Advanced Water Meters, 2017 - 2025 (USD Million)
5. Keyword Market, By Service, 2017 - 2025 (USD Million)
6. Keyword Market, By Solution, 2017 - 2025 (USD Million)
7. Keyword Market, By Regions, 2017 - 2025 (USD Million)
8. Competitive Landscape
Ask for Discount before Buying @
https://www.coherentmarketinsights.com/insight/request-discount/109
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com